Skip to main content

Keep up to date with the latest news about Trogenix’s progress, events, and breakthroughs in cancer treatment.

Navigate to the next section
04_News & Events.

04_News & Events.

Filter Trogenix News & Events.

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher
May 7, 2025

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
BiotechTV Tour of Scotland
March 14, 2025

BiotechTV Tour of Scotland

Edinburgh-based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumour Amy Brown…
Read More
2024 Achievements and 2025 Outlook
December 19, 2024

2024 Achievements and 2025 Outlook

Accelerating Toward the Clinic in 2025 Trogenix has successfully achieved all milestones in platform and asset development, positioning the company to enter the clinic in…
Read More
Trogenix unveils odyssey to find one-time tumor drugs with ‘unprecedented selectivity’.
November 18, 2024

Trogenix unveils odyssey to find one-time tumor drugs with ‘unprecedented selectivity’.

Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments. Equipped with £15 million ($19…
Read More
Scottish biotech debuts with ‘Trojan horse’ platform for cancer
November 18, 2024

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…
Read More
Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.
November 18, 2024

Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.
November 1, 2024

World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.

Trogenix recently hosted a landmark workshop at The Royal College of Surgeons in Edinburgh, uniting pioneering experts in neurosurgery, gene therapy, and oncology to advance…
Read More
Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.
January 15, 2024

Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.

Grant will accelerate development and evaluate Trogenix’s SSE technology in liver hepatocellular carcinoma and colorectal cancer liver metastases Edinburgh, UK, January 2024 - Trogenix Ltd…
Read More
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher
May 7, 2025

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
2024 Achievements and 2025 Outlook
December 19, 2024

2024 Achievements and 2025 Outlook

Accelerating Toward the Clinic in 2025 Trogenix has successfully achieved all milestones in platform and asset development, positioning the company to enter the clinic in…
Read More
Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.
November 18, 2024

Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.
November 1, 2024

World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.

Trogenix recently hosted a landmark workshop at The Royal College of Surgeons in Edinburgh, uniting pioneering experts in neurosurgery, gene therapy, and oncology to advance…
Read More
Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.
January 15, 2024

Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.

Grant will accelerate development and evaluate Trogenix’s SSE technology in liver hepatocellular carcinoma and colorectal cancer liver metastases Edinburgh, UK, January 2024 - Trogenix Ltd…
Read More
BiotechTV Tour of Scotland
March 14, 2025

BiotechTV Tour of Scotland

Edinburgh-based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumour Amy Brown…
Read More
Trogenix unveils odyssey to find one-time tumor drugs with ‘unprecedented selectivity’.
November 18, 2024

Trogenix unveils odyssey to find one-time tumor drugs with ‘unprecedented selectivity’.

Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments. Equipped with £15 million ($19…
Read More
Scottish biotech debuts with ‘Trojan horse’ platform for cancer
November 18, 2024

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…
Read More